CMRA (Comera Life Sciences Holdings) EBITDA Margin %: -1,562.50% (As of Sep. 2023)


What is Comera Life Sciences Holdings EBITDA Margin %?

Comera Life Sciences Holdings CMRA EBITDA Margin % is -1,562.50% as of Sep. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Comera Life Sciences Holdings's EBITDA for the three months ended in Sep. 2023 was $-2.13 Mil. Comera Life Sciences Holdings's Revenue for the three months ended in Sep. 2023 was $0.14 Mil. Therefore, Comera Life Sciences Holdings's EBITDA margin for the quarter that ended in Sep. 2023 was -1,562.50%.

Comera Life Sciences Holdings  (OTCPK:CMRA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Comera Life Sciences Holdings EBITDA Margin % Related Terms

Comera Life Sciences Holdings EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Comera Life Sciences Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comera Life Sciences Holdings EBITDA Margin % Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
EBITDA Margin %
-460.05 -1,676.88 -2,826.22

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1,293.62 -1,878.85 -622.14 -439.05 -1,562.50

CMRA vs FREQ, BNTC, IMNN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Comera Life Sciences Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Comera Life Sciences Holdings EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's EBITDA Margin % falls into.


Comera Life Sciences Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Comera Life Sciences Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-17.89/0.633
=-2,826.22 %

Comera Life Sciences Holdings's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-2.125/0.136
=-1,562.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -1,562.50% mean?
Comera Life Sciences Holdings (CMRA) has a EBITDA Margin % of -1,562.50% as of Sep. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Comera Life Sciences Holdings and its competitors.
Is Comera Life Sciences Holdings' EBITDA Margin % too high?
Comera Life Sciences Holdings' current EBITDA Margin % is -1,562.50%.
How does Comera Life Sciences Holdings' EBITDA Margin % compare to FREQ and BNTC?
Comera Life Sciences Holdings' EBITDA Margin % of -1,562.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Comera Life Sciences Holdings and its competitors. Comera Life Sciences Holdings's current EBITDA Margin % is -1,562.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRA) has a current EBITDA Margin % of -1,562.50%. The current EBITDA Margin % is -1,562.50%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRA), the current EBITDA Margin % is -1,562.50% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Comera Life Sciences Holdings Business Description

Address 12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.